Germinal Centers Drive Consistent Antibody Improvement Through a Surprisingly Random Process

A new study tracking thousands of B cells across more than 100 germinal centers in mice has revealed how the immune system consistently produces highly effective antibodies—and the answer challenges longstanding assumptions about how that process works. The findings, from the Laboratory of Lymphocyte Dynamics at Rockefeller University, show that germinal centers are far more selective than previously thought, and that antibody improvement is not driven by rare growth bursts among the most successful B cells, but by a slightly biased, repeatedly noisy process that averages out across many germinal centers.

“The traditional, mechanistic view of germinal centers is to think of them as selection machines sorting out the best antibodies,” said Gabriel D. Victora, senior author of the study published in Cell. “But when you look very, very closely, you see a process that's almost essentially random—a little bit better than a coin toss—which repeats many times until the immune system arrives at the right answer consistently. That's much more akin to how evolution operates than the way a machine does.” 

Inside germinal centers, B cells rapidly mutate and compete to produce antibodies with successively better binding affinity to pathogens. To study this process with precision, Victora’s team engineered mice in which all competing B cells began with the same antibody sequence, allowing them to observe the same evolutionary process play out independently across more than 100 germinal centers simultaneously.

Using multiphoton microscopy, laser-based photoactivation, and single-cell sequencing of thousands of B cells across 119 germinal centers, they constructed detailed family trees mapping how different B cell lineages developed.

The team also built a mutational dictionary using Deep Mutational Scanning (DMS), a technique that links nearly every possible amino acid change to antibody performance. “DMS was the big technical advance here,” said first author Ashni Vora. “With it we could determine the affinities of thousands of cells just by looking at their sequence, without having to produce an antibody.”

The resulting picture resembled a casino. Individual germinal centers looked almost random—some overtaken by clonal bursts, others containing many competing lineages with no clear winner. But the team found the system is subtly rigged in favor of beneficial mutations. Each round of competition is only slightly biased toward higher-affinity cells, and random chance means there is often little correlation between affinity and success in any single germinal center. Repeated across many germinal centers, however, that small bias consistently produces stronger antibodies.

“If there are a thousand people playing, it’s going to average out and the house wins. That’s essentially how germinal centers work,” Victora said.

The researchers also found that the immune system favors mutations that are easiest for its cellular machinery to generate, rather than those that would produce the strongest antibodies—and that germinal centers eliminate inferior B cells far more rapidly than previously appreciated.

The findings may provide new tools for vaccine developers hoping to steer antibody evolution against rapidly mutating pathogens like influenza and HIV. They also point to germinal centers as a powerful model for studying evolution more broadly. Unlike bacteria, which adapt to many possible survival strategies, B cells all aim for the same target—making them a potentially more tractable experimental system. “I see this as an opening salvo in a longer effort to understand evolution by using the immune system as a model,” Victora added.